Surfaxin approval will hinge on preclinical work

Shares of Discovery Labs (DSCO) shot up 10 percent this morning after the developer announced that it would only need to conduct new animal studies of its experimental therapy Surfaxin for respiratory illness in children rather than a new clinical trial. "Compared to the conduct of a PD clinical trial, a comprehensive preclinical program, if successful, presents an opportunity to significantly reduce the time and expense required to gain potential Surfaxin approval," the company said. Report

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.